

Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results	20th November, 2009	Landauer, Inc.	GLENWOOD, Ill., Nov. 20 /PRNewswire-FirstCall/ -- Landauer, Inc. (NYSE: LDR), will release financial results for the fiscal fourth quarter and full year of 2009 pre-market on Tuesday, December 1, 2009
PhRMA Stands by Its Commitment to Health Reform	20th November, 2009	Pharmaceutical Research and Manufacturers of America	WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- POLITICO recently published an editorial by Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson. In the
Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013
Reportlinker Adds Medical Adhesives and Sealants - A US Market Review	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Medical Adhesives and Sealants - A US Market Review http://www
Reportlinker Adds Global Markets for Breast Biopsy Devices 2009	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Global Markets for Breast Biopsy Devices 2009 http://www.reportlinker.com

BioNews Results for Johnson and Johnson (France)



- [Commercial Insight: Anticonvulsants - Non-epilepsy label expansions provide blockbuster potential - new report](#)
PR inside: Nov 3 2009 7:37PM Matching: johnson france
- [Sunday start for Amgen Tour considered a boon for tourism](#)
San Francisco Business Times: Oct 30 2009 9:20PM Matching: johnson france
- [Analysis of the current and future anticonvulsant drug class market](#)
News-Medical.Net: Oct 29 2009 9:33AM Matching: johnson france
- [Winning placement on Managed Care formularies, the first step for product's increased market share](#)
News-Medical.Net: Oct 29 2009 10:20AM Matching: johnson france

- [Research and Markets: Commercial Insight: Anticonvulsants - Non-Epilepsy Label Expansions](#)
Forbes.com: Oct 28 2009 4:29PM Matching: johnson france
- [Research and Markets: Commercial Insight: Anticonvulsants - Non-Epilepsy Label Expansions Provide Blockbuster](#)
Business Wire: Oct 28 2009 4:10PM Matching: johnson france
- [Research and Markets: Commercial Insight: Anticonvulsants - Non-Epilepsy Label Expansions Provide Blockbuster Potential Analyse Forecasts Up To 2018](#)
Earthtimes.org: Oct 28 2009 4:08PM Matching: johnson france
- [Research and Markets: Commercial Insight: Anticonvulsants - Non-Epilepsy Label Expansions Provide Blockbuster](#)
RBC Dain Rauscher: Oct 28 2009 4:08PM Matching: johnson france
- [Research and Markets: Commercial Insight: Anticonvulsants - Non-Epilepsy Label Expansions Provide Blockbuster](#)
Yahoo! Canada: Oct 28 2009 4:07PM Matching: johnson france
- [Research and Markets: Commercial Insight: Anticonvulsants - Non-Epilepsy Label Expansions Provide Blockbuster](#)
Business Wire via Yahoo!: Oct 28 2009 4:04PM Matching: johnson france
- [Research and Markets: Commercial Insight: Anticonvulsants - Non-Epilepsy Label Expansions Provide Blockbuster](#)
Business Wire UK: Oct 28 2009 4:04PM Matching: johnson france
- [Research and Markets: Commercial Insight: Anticonvulsants - Non-Epilepsy Label Expansions Provide Blockbuster](#)
Business Wire: Oct 28 2009 4:02PM Matching: johnson france
- [Research and Markets: Commercial Insight: Anticonvulsants - Non-Epilepsy Label Expansions Provide Blockbuster](#)
PR inside: Oct 28 2009 4:20PM Matching: johnson france
- [Commercial Insight: Anticonvulsants - Non-epilepsy label expansions provide blockbuster potential By Bharatboo](#)
PRMinds: Oct 28 2009 4:03PM Matching: johnson france
- [Amgen 2010 Tour's first leg: Nevada City to Sacramento](#)
Sacramento Business Journal: Oct 24 2009 3:30AM Matching: johnson france

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

